Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the move! Covid Vaccine Player >>> Cold Chain issues? Unlike a traditional logistic solution, a cold chain independent, thermostable solid form vaccines is a breakthrough solution.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine and recently with Insel Gruppe AG in developing a covid vaccine. News is imminent on status updates.
On the move! Covid Vaccine player. Cold Chain issues? Unlike a traditional logistic solution, a cold chain independent, thermostable solid form vaccines is a breakthrough solution.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine and recently with Insel Gruppe AG in developing a covid vaccine. News is imminent on status updates.
Cold Chain issues? Unlike a traditional logistic solution, a cold chain independent, thermo stable solid form vaccines is a breakthrough solution.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine and recently with Insel Gruppe AG in developing a covid vaccine. News is imminent on status updates.
Cold Chain issues? Unlike a traditional logistic solution, a cold chain independent, thermo stable solid form vaccines is a breakthrough solution.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine and recently with Insel Gruppe AG in developing a covid vaccine. News is imminent on status updates.
Cold Chain issues? Unlike CYRX's logistic solution, a cold chain independent, thermo stable solid form vaccines is a breakthrough solution.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine and recently with Insel Gruppe AG in developing a covid vaccine. News is imminent on status updates.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine in developing a covid vaccine. News is imminent on status updates.
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine in developing a covid vaccine. News is imminent on status updates.
COVID-19 NEWS! MYMX
MYMX awaken on Covid 19 vaccine news!!!
MYMETICS STARTS PRECLINICAL STUDIES WITH BAYLOR COLLEGE OF MEDICINE FOR VIROSOME-BASED COVID-19 VACCINE
https://www.mymetics.com/media-center/mymetics-starts-preclinical-studies-baylor-college-medicine-virosome-based-covid-19-vaccine/
MYMX just awaken due to Covid 19 NEWS!!!
Been waiting. It's about time!
BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering
https://www.otcmarkets.com/stock/BIVI/news/BioVie-Inc-Announces-Nasdaq-Listing-and-Pricing-of-157-Million-Public-Offering?id=274402
Gonna be a big player in NASH related industry.
GL
Rule 36 JUDGMENT
* Rule 36 affirmance is a quick and clean decision
* Nearly impossible to challenge by rehearing
* Nearly impossible to seek Supreme Court certiorari
https://www.google.nl/url?sa=t&source=web&rct=j&url=https://udayton.edu/law/_resources/documents/pilt_2019_seminar_materials/pilt_galluzzo_federal_circuit_rule36.pdf&ved=2ahUKEwj6xsaMr4fqAhUc4OAKHSbNDA8QFjACegQIARAB&usg=AOvVaw2gDMyn1daxonl5AKijgFaQ&cshid=1592346006394
The Affirmance/Judgment
http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1720.RULE_36_JUDGMENT.6-15-2020_1603464.pdf
Rule 36 JUDGMENT
* Rule 36 affirmance is a quick and clean decision
* Nearly impossible to challenge by rehearing
* Nearly impossible to seek Supreme Court certiorari
https://www.google.nl/url?sa=t&source=web&rct=j&url=https://udayton.edu/law/_resources/documents/pilt_2019_seminar_materials/pilt_galluzzo_federal_circuit_rule36.pdf&ved=2ahUKEwj6xsaMr4fqAhUc4OAKHSbNDA8QFjACegQIARAB&usg=AOvVaw2gDMyn1daxonl5AKijgFaQ&cshid=1592346006394
The Affirmance/Judgment
http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1720.RULE_36_JUDGMENT.6-15-2020_1603464.pdf
Google lost a decade IP battle vs. a microcap Netlist
The Steady Rise of Netlist, Inc. (OTCMKTS: NLST)
"On June 16 NLST announced the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed the U.S. Patent Trial and Appeal Board’s (PTAB) decision upholding the validity of Netlist’s U.S. 7,619,912 (‘912) patent. The ruling came after last week’s oral hearing before a three-judge panel at the Federal Circuit and pending an appeal granted by the Supreme Court of the U.S., the decision is final and binding on future cases. In response to Netlist’s 2009 complaint, Google first filed its petition for reexamination of the ‘912 patent in 2010 and was later joined in its effort by Inphi and Smart Modular. On January 31, 2019 PTAB denied Google’s request for a rehearing of the PTAB’s previous decision upholding the validity of the ‘912 patent claims. The PTAB’s extensive rehearing decision adopted Netlist’s positions on the claims and rejected Google’s invalidity arguments involving the specific use of rank-selecting signals for rank multiplication"
"NLST CEO C.K. Hong stated: “For ten years Netlist has steadfastly opposed Google’s misguided campaign to invalidate the ‘912 patent. We are very pleased that in the end the appellate court made it clear that the claims of this seminal patent are indeed valid and in so doing, further vindicate our decade-long defense of the company’s strategic intellectual property. We will now move to lift the stay in the patent infringement lawsuit against Google in the U.S. District Court for the Northern District of CA., in order to recover current and past damages related to the ‘912 patent.”
https://microcapdaily.com/the-steady-rise-of-netlist-inc-otcmkts-nlst/126280/
Google lost a decade IP battle vs. a microcap Netlist
The Steady Rise of Netlist, Inc. (OTCMKTS: NLST)
"On June 16 NLST announced the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed the U.S. Patent Trial and Appeal Board’s (PTAB) decision upholding the validity of Netlist’s U.S. 7,619,912 (‘912) patent. The ruling came after last week’s oral hearing before a three-judge panel at the Federal Circuit and pending an appeal granted by the Supreme Court of the U.S., the decision is final and binding on future cases. In response to Netlist’s 2009 complaint, Google first filed its petition for reexamination of the ‘912 patent in 2010 and was later joined in its effort by Inphi and Smart Modular. On January 31, 2019 PTAB denied Google’s request for a rehearing of the PTAB’s previous decision upholding the validity of the ‘912 patent claims. The PTAB’s extensive rehearing decision adopted Netlist’s positions on the claims and rejected Google’s invalidity arguments involving the specific use of rank-selecting signals for rank multiplication"
"NLST CEO C.K. Hong stated: “For ten years Netlist has steadfastly opposed Google’s misguided campaign to invalidate the ‘912 patent. We are very pleased that in the end the appellate court made it clear that the claims of this seminal patent are indeed valid and in so doing, further vindicate our decade-long defense of the company’s strategic intellectual property. We will now move to lift the stay in the patent infringement lawsuit against Google in the U.S. District Court for the Northern District of CA., in order to recover current and past damages related to the ‘912 patent.”
https://microcapdaily.com/the-steady-rise-of-netlist-inc-otcmkts-nlst/126280/
Grant Pickering, MBA -Vaxcyte, President & Chief Executive Officer, Director and Founder
Grant has nearly 30 years of experience in the pharmaceutical and biotech arena having responsibility for multiple vaccines and immunotherapeutic drug approvals and the formation and financing of multiple successful platform companies. Prior to starting Vaxcyte, Mr. Pickering was the CEO of Mymetics Corporation, a public European-based vaccine company developing a prophylactic RSV vaccine, based on a virosomal platform technology. Prior to that, he was an executive-in-residence at Kleiner, Perkins, Caufield & Byers, while serving as the CEO at Juvaris BioTherapeutics, whose immunotherapeutic and vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. Prior to Juvaris, Mr. Pickering spent many years at Dendreon Corporation where he played a prominent role in the company’s IPO and led clinical development, operations and business development culminating in the launch of the therapeutic prostate cancer vaccine, Provenge®. He also led marketing and business development for the pain management platform company, Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals. Mr. Pickering began his career at Glaxo and Johnson & Johnson in sales, marketing, and clinical research roles culminating in the launches of Flonase® and Floxin®. Mr. Pickering earned his BS degree in marketing from The Pennsylvania State University and his MBA from Georgetown University with high honors. Outside of Vaxcyte, Grant enjoys spending time with his wife and kids, living vicariously through their soccer triumphs, and gives back through mentoring and supporting education both domestically and in developing countries. Grant’s loyalty to his hometown of Kansas City was finally doubly rewarded as both the Royals and the Chiefs were crowned world champions since Vaxcyte got rolling.
https://vaxcyte.com/about-us/management-team/
Mymetics Corp. (otcqb: MYMX) https://www.mymetics.com/about/
Rule 36 JUDGMENT
* Rule 36 affirmance is a quick and clean decision
* Nearly impossible to challenge by rehearing
* Nearly impossible to seek Supreme Court certiorari
https://www.google.nl/url?sa=t&source=web&rct=j&url=https://udayton.edu/law/_resources/documents/pilt_2019_seminar_materials/pilt_galluzzo_federal_circuit_rule36.pdf&ved=2ahUKEwj6xsaMr4fqAhUc4OAKHSbNDA8QFjACegQIARAB&usg=AOvVaw2gDMyn1daxonl5AKijgFaQ&cshid=1592346006394
The Affirmance/Judgment
http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1720.RULE_36_JUDGMENT.6-15-2020_1603464.pdf
Netlist Prevails against Google at the U.S. Federal Circuit Court of Appeals
IRVINE, CA / ACCESSWIRE / June 16, 2020 / Netlist, Inc. (NLST) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed the U.S. Patent Trial and Appeal Board's (PTAB) decision upholding the validity of Netlist's U.S. 7,619,912 (‘912) patent. The ruling came after last week's oral hearing before a three-judge panel at the Federal Circuit and pending an appeal granted by the Supreme Court of the U.S., the decision is final and binding on future cases...
"We will now move to lift the stay in the patent infringement lawsuit against Google in the U.S. District Court for the Northern District of CA., in order to recover current and past damages related to the ‘912 patent"
https://finance.yahoo.com/news/netlist-prevails-against-google-u-110000922.html
Rule 36 Basics
* Rule 36 affirmance is a quick and clean decision
* Nearly impossible to challenge by rehearing
* Nearly impossible to seek Supreme Court certiorari
https://www.google.nl/url?sa=t&source=web&rct=j&url=https://udayton.edu/law/_resources/documents/pilt_2019_seminar_materials/pilt_galluzzo_federal_circuit_rule36.pdf&ved=2ahUKEwj6xsaMr4fqAhUc4OAKHSbNDA8QFjACegQIARAB&usg=AOvVaw2gDMyn1daxonl5AKijgFaQ&cshid=1592346006394
Netlist prevailed a decade IP battle against Google...
http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1720.RULE_36_JUDGMENT.6-15-2020_1603464.pdf
Netlist prevails a decade IP battle against Google at The US Federal Circuit Court Of Appeals
https://www.netlist.com/investors/financial-news/press-release-details/2020/Netlist-Prevails-against-Google-at-the-US-Federal-Circuit-Court-of-Appeals/default.aspx
Google lost a decade IP battle to Netlist at the Federal Circuit Court of Appeals
https://www.netlist.com/investors/financial-news/press-release-details/2020/Netlist-Prevails-against-Google-at-the-US-Federal-Circuit-Court-of-Appeals/default.aspx
Google lost a decade IP battle to Netlist at the Federal Circuit Court of Appeals
https://www.netlist.com/investors/financial-news/press-release-details/2020/Netlist-Prevails-against-Google-at-the-US-Federal-Circuit-Court-of-Appeals/default.aspx
Good to go! Today, EU health ministers gave "overwhelming" backing for a Commission plan to use an emergency fund of currently 2.4 billion euros ($2.7 billion) to buy coronavirus vaccines upfront, Health Commissioner Stella Kyriakides told journalists after a videoconference with representatives of the 27 EU governments.
Under the plan, the EU would use most of the money available in that fund to buy in advance up to six vaccines for its 450 million people, EU officials said.
The commissioner said the EU executive had already discussed its plans with pharmaceutical companies, but declined to name them. She also did not answer questions about the timing of the possible advance purchasing deals.
https://finance.yahoo.com/news/eu-urges-joint-efforts-blocs-124411784.html
Go NVAX!
There is a good chance Novavax will get a piece of the pie - something to look forward to next week. imo
EU wants to buy COVID-19 vaccines up front - unless they're made in America
BRUSSELS, June 11 (Reuters) - The European Commission is seeking a mandate from EU countries to buy promising COVID-19 vaccine candidates in advance from pharmaceutical firms, as long as they are not produced solely in the United States, officials said.
The EU executive wants to pay for up to six potential vaccines in deals where the makers would commit to providing doses when and if they become available.
It will ask EU health ministers at a video conference meeting on Friday to back the plan, which has been swiftly devised as the bloc fears it may not have access to enough shots should a vaccine be developed.
All vaccines in clinical trial this year are in principle eligible for advance purchases, but not those which are produced exclusively in the United States, because Washington has signalled it will not allow sales abroad before its own needs are met, the EU officials told a news conference.
"Sourcing from producers that would only have production capacity in the United States would not really be an option for us," one Commission official said, adding this would not guarantee that the shots are available for the EU population.
British-based drugmakers AstraZeneca and GlaxoSmithKline, France's Sanofi, and U.S. players Pfizer, Novavax, Johnson & Johnson and Moderna are among companies trialling vaccines. See FACTBOX for full list and details:
The Commission official said U.S. companies with production facilities in Europe could be eligible. Asked which companies could be excluded from EU deals, she said it was too early to say.
The plan would offer financial guarantees to pharmaceutical companies, which face big losses if their vaccines are not successful.
"We pay up front a significant part of the investment needed in exchange for a commitment from the pharmaceutical manufacturer to give us a vaccine when is available," the official told a news conference.
The purchase agreements would be financed with an EU emergency fund, which currently has a budget of 2.4 billion euros ($2.7 billion), officials said, confirming Reuters' earlier reports.
EU governments, which are negotiating deals with pharmaceutical companies on their own, could also provide extra funding, the official said. It is not clear whether the plan has the backing of EU member states, however.
As part of the plan, the Commission will also propose a temporary softening of regulatory requirements to develop vaccines that contain genetically modified organisms (GMOs), officials said, confirming an earlier Reuters report .
If backed by EU health ministers on Friday, the Commission will make formal proposals next week. (Reporting by Francesco Guarascio @fraguarascio; Editing by Elaine Hardcastle, Mark Potter and Pravin Char)
https://news.trust.org/item/20200611145709-s4bc5
Go NVAX!
BTHE - In the first half of 2020 we anticipate the announcement of the phase 2 exploratory trial for our pivitol phase 3. This is anticipated to confirm the safety and efficacy for the potential drug filing of the investigative materials.
page 15 >>>
https://www.sec.gov/Archives/edgar/data/1473579/000121390020014377/f10k2019_bostontherapeutics.htm
Results any day now....
Status of Development of SUGARDOWN®
We completed development of SUGARDOWN® as an over the counter (OTC) US dietary supplement. We filed a structure and function claim application with the United States Food and Drug Administration (FDA) with respect to SUGARDOWN®, which describes the proposed mechanism of action of SUGARDOWN® in reducing post-meal elevation of glucose in the blood. We have submitted thirty structural and functional claims with the FDA. We currently have strategically received awarded patents that are directed to the Composition of purified mannans, which are utilized in the formulation of SUGARDOWN®. We have also received a registered mark for SUGARDOWN®. General Product Liability Insurance for SUGARDOWN® has been in effect since April 2010. On January 24, 2012, we announced the clinical test results in healthy volunteers performed at the Sydney University Glycemic Institute for Research with SUGARDOWN®. On January 28, 2013, we announced the final results of the study conducted at the University of Sydney that showed the post- meal incremental area under the curve (iAUC) for glucose and insulin were significantly lower following consumption of SUGARDOWN® tablets prior to a high carbohydrate meal of rice in a dose-dependent manner. This resulted in a reduction of up to 61% in post-meal elevation of blood glucose compared with the rice consumed alone. On average, there was a 25.5% reduction in the post-meal iAUC for glucose and a 20% reduction in post-meal insulin response for the 10 volunteers in the study. No severe adverse effects were reported or observed during the study. As of December 2019 we have been party to the completion of several additional clinical trials all supported by Clinical.trials.gov. and we are publishing to secure a standing and to confirm the integrity of the data. In the first half of 2020 we anticipate the announcement of the phase 2 exploratory trial for our pivitol phase 3. This is anticipated to confirm the safety and efficacy for the potential drug filing of the investigative materials.
page 15 >>>
https://www.sec.gov/Archives/edgar/data/1473579/000121390020014377/f10k2019_bostontherapeutics.htm
Results any day now....
No mention anything about "restaurant systems" Under the Subsequent Events (last page) except for a $300K loan???- This makes the recent 8-k filing confusing. Must be a mistake? WEIRD!!!
https://www.sec.gov/Archives/edgar/data/1473579/000121390020014377/f10k2019_bostontherapeutics.htm
3 Top Coronavirus Stocks to Buy in June
https://www.fool.com/investing/2020/06/06/3-top-coronavirus-stocks-to-buy-in-june.aspx
Why Is Everyone Talking About Novavax Stock?
https://www.fool.com/investing/2020/06/06/why-is-everyone-talking-about-novavax-stock.aspx
3 Top Coronavirus Stocks to Buy in June
https://www.fool.com/investing/2020/06/06/3-top-coronavirus-stocks-to-buy-in-june.aspx
3 Top Coronavirus Stocks to Buy in June
https://www.fool.com/investing/2020/06/06/3-top-coronavirus-stocks-to-buy-in-june.aspx
BTHE - A new beginnings??? Still wondering all of a sudden, the company has restaurant systems?
Very eager for confirmation/clarification here. Hello?
Hoping for the best!
SEC 13G Filed today. D. E. Shaw & Co., L.L.C. Bought 2,902,232 shares (5% ownership)
https://www.sec.gov/Archives/edgar/data/1000694/000110465920068349/tm2021497d1_sc13g.htm
Dr. Stanley Plotkin "The Father Of Vaccines", INO Scientific Advisory Board.
Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult
Stanley Plotkin developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines, including polio, rabies, varicella, rotavirus, and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and is a principal of Vaxconsult.
Over the course of his career he has served as senior assistant surgeon with the Epidemic Intelligence Service of the U.S. Public Health Service; Chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics; Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health; director of the Division of Infectious Diseases at Children’s Hospital of Philadelphia; Associate Chairman of the Department of Pediatrics, University of Pennsylvania; Medical and Scientific Director of Aventis Pasteur; and Executive Advisor to Sanofi Pasteur. Over 600 of his articles have been published, and he has edited several books, including Vaccines, now the standard textbook in the field.
Dr. Plotkin’s numerous professional awards include:
The medal of the Fondation Mérieux (2007)
The Fleming (Bristol) Award of the Infectious Diseases Society of America (2004)
The Sabin Foundation Medal (2002)
The French Legion Medal of Honor (1998)
The Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis (1995)
The Distinguished Physician Award, Pediatric Infectious Disease Society (1993)
The Bruce Medal of the American College of Physicians (1987)
Dr. Plotkin earned his M.D. at the State University of New York, Downstate College of Medicine, and holds honorary degrees from the University of Pennsylvania and the University of Rouen (France). He serves on the Board of Directors of Dynavax and is Chairman of the Scientific Advisory Board of Mymetics, while also serving as an International Society for Vaccines advisor.
https://www.inovio.com/about-inovio/scientific-advisory-board/
Chairman of Scientific Advisory Board of an unknown penny stock company?
Dr. Stanley Plotkin "The Father Of Vaccines", INO Scientific Advisory Board.
Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult
Stanley Plotkin developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines, including polio, rabies, varicella, rotavirus, and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and is a principal of Vaxconsult.
Over the course of his career he has served as senior assistant surgeon with the Epidemic Intelligence Service of the U.S. Public Health Service; Chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics; Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health; director of the Division of Infectious Diseases at Children’s Hospital of Philadelphia; Associate Chairman of the Department of Pediatrics, University of Pennsylvania; Medical and Scientific Director of Aventis Pasteur; and Executive Advisor to Sanofi Pasteur. Over 600 of his articles have been published, and he has edited several books, including Vaccines, now the standard textbook in the field.
Dr. Plotkin’s numerous professional awards include:
The medal of the Fondation Mérieux (2007)
The Fleming (Bristol) Award of the Infectious Diseases Society of America (2004)
The Sabin Foundation Medal (2002)
The French Legion Medal of Honor (1998)
The Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis (1995)
The Distinguished Physician Award, Pediatric Infectious Disease Society (1993)
The Bruce Medal of the American College of Physicians (1987)
Dr. Plotkin earned his M.D. at the State University of New York, Downstate College of Medicine, and holds honorary degrees from the University of Pennsylvania and the University of Rouen (France). He serves on the Board of Directors of Dynavax and is Chairman of the Scientific Advisory Board of Mymetics, while also serving as an International Society for Vaccines advisor.
https://www.inovio.com/about-inovio/scientific-advisory-board/
Chairman of Scientific Advisory Board of an unknown penny stock company?
Thanks Bluechip$, Great news today! CVS is a huge deal!
Wondering if their TV awareness adds already launched?
Something strange happened here.??? Definitely for GOOD ???
From the prior SEC filing/s (particularly the previous 8-k), no such thing was indicated.
What is this???? I'm not aware that BTHE has RESTAURANT SYSTEMS???
Did I miss something??? Was there a M&A happened??? hmmmmmm.... interesting!
The Company’s restaurant system which currently consists of company operated restaurants and franchised restaurants are located throughout the United States including in areas such as California, New Jersey and New York that have been hardest hit by the COVID-19 epidemic. As a result of the COVID 19 epidemic, management’s full efforts have been focused on operating its business, evaluating available funding and working with its franchisees, vendors and employees. Further, the Company has been following the recommendations of local health authorities to minimize exposure risk for its team members for the past several weeks, including the temporary closures of its corporate offices and having team members work remotely. As such, the Company previously disclosed that its finance team will be unable to complete the preparation of the Company’s consolidated financial statements and the Form 10-K until after March 30, 2020.
These unforeseen circumstances have resulted in the Company being unable to timely file an accurate Annual Report on Form 10-K for its year-ended December 31, 2019 by the prescribed date without undue hardship and expense to the Company. Accordingly, in reliance upon the Order, the Company expects to file its Annual Report on Form 10-K no later than 45 days after the due date of filing of March 30, 2020, unless the COVID-19 circumstances do not change and cause a further delay, in which case we will file for an additional extension and amendment to this Current Report on Form 8-K. The Company will not to file its Annual Report on or prior to May 14, 2020 and will file the Form 12b-25 Notification of Late Filing providing that the Annual Report will be filed on or before the 15th calendar day following the prescribed due date.
For the same reasons, the Company will be unable to timely file its Form 10-Q Quarterly Report for the period ended March 31, 2020, which is due on May 15, 2020. The Company, in reliance upon the Order, expects that it will be able to file each of its Annual Report and Quarterly report within 45 days of the due date of each respective report.
https://www.otcmarkets.com/filing/html?id=14156120&guid=QFMHU6uprzLfI3h
UPTREND easy gap up 10 bagger from here with the right news! imo
Good Luck!